54.25
price up icon1.31%   0.70
after-market 시간 외 거래: 54.25
loading
전일 마감가:
$53.55
열려 있는:
$54.15
하루 거래량:
1.31M
Relative Volume:
0.60
시가총액:
$6.91B
수익:
$947.36M
순이익/손실:
$392.47M
주가수익비율:
17.96
EPS:
3.02
순현금흐름:
$392.71M
1주 성능:
-3.25%
1개월 성능:
-8.64%
6개월 성능:
+12.09%
1년 성능:
+5.46%
1일 변동 폭
Value
$53.44
$54.76
1주일 범위
Value
$52.73
$56.32
52주 변동 폭
Value
$42.01
$70.50

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Name
명칭
Halozyme Therapeutics Inc
Name
전화
(858) 794-8889
Name
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
Name
직원
350
Name
트위터
@halozymeinc
Name
다음 수익 날짜
2025-02-18
Name
최신 SEC 제출 서류
Name
HALO's Discussions on Twitter

HALO을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
HALO
Halozyme Therapeutics Inc
54.25 6.91B 947.36M 392.47M 392.71M 3.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 113.52B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 52.93B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
300.83 39.71B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
585.93 35.00B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.57B 3.81B -644.79M -669.77M -6.24

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-05-14 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2025-05-13 다운그레이드 Leerink Partners Market Perform → Underperform
2024-10-07 다운그레이드 Wells Fargo Overweight → Equal Weight
2024-09-19 다운그레이드 JP Morgan Overweight → Neutral
2024-06-07 다운그레이드 Piper Sandler Overweight → Neutral
2024-02-29 개시 TD Cowen Outperform
2023-07-24 다운그레이드 Goldman Buy → Neutral
2023-07-24 개시 H.C. Wainwright Buy
2023-05-10 업그레이드 Piper Sandler Neutral → Overweight
2023-03-27 재개 Berenberg Buy
2023-03-16 다운그레이드 SVB Securities Outperform → Market Perform
2022-12-21 재개 Morgan Stanley Overweight
2022-11-28 개시 Wells Fargo Overweight
2022-09-09 개시 Morgan Stanley Overweight
2022-05-23 개시 SVB Leerink Outperform
2021-06-14 개시 Evercore ISI Outperform
2021-05-17 개시 SVB Leerink Outperform
2021-05-11 다운그레이드 Piper Sandler Overweight → Neutral
2021-01-21 재확인 The Benchmark Company Buy
2020-12-17 개시 Berenberg Buy
2020-09-14 재개 JP Morgan Overweight
2020-07-01 개시 The Benchmark Company Buy
2020-02-05 업그레이드 Piper Sandler Neutral → Overweight
2020-01-09 업그레이드 BMO Capital Markets Market Perform → Outperform
2020-01-08 개시 Goldman Buy
2019-11-05 업그레이드 Barclays Underweight → Equal Weight
2018-10-19 재개 Piper Jaffray Neutral
2018-05-11 다운그레이드 Barclays Equal Weight → Underweight
2018-01-24 개시 Goldman Neutral
2017-10-16 재확인 Piper Jaffray Overweight
2017-01-06 다운그레이드 Citigroup Buy → Neutral
2016-11-03 개시 Deutsche Bank Buy
2015-12-04 개시 Wells Fargo Outperform
2015-11-18 개시 Citigroup Buy
2015-09-22 개시 Barclays Overweight
2015-06-22 재확인 JP Morgan Overweight
2015-03-03 재확인 UBS Buy
2015-02-18 재확인 MLV & Co Buy
2015-01-08 재확인 MLV & Co Buy
모두보기

Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스

pulisher
11:18 AM

Merck gains U.S. patent office support in Keytruda dispute - MSN

11:18 AM
pulisher
Jun 05, 2025

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - mx.advfn.com

Jun 05, 2025
pulisher
Jun 05, 2025

Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years - Benzinga

Jun 04, 2025
pulisher
Jun 04, 2025

Merck (MRK) Gains Edge in Keytruda Patent Dispute - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Merck dispute with Halozyme over Keytruda injection to get another USPTO look - Seeking Alpha

Jun 04, 2025
pulisher
Jun 04, 2025

Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) for the Valuation Discipline - Insider Monkey

Jun 04, 2025
pulisher
Jun 04, 2025

PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

Merck granted review of Halozyme patent claims by PTAB - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

Zacks.com featured highlights Sterling Infrastructure, BJ's Wholesale, Molina Healthcare and Halozyme - Yahoo Finance

Jun 04, 2025
pulisher
Jun 03, 2025

Halozyme (HALO) Faces Patent Challenge as USPTO Institutes Revie - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Halozyme (HALO) Faces Patent Challenges Affecting Stock Outlook | HALO Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Here’s Why Halozyme Therapeutics (HALO) Rebounded in Q1 - Insider Monkey

Jun 03, 2025
pulisher
Jun 02, 2025

(HALO) Investment Report - news.stocktradersdaily.com

Jun 02, 2025
pulisher
May 31, 2025

H.C. Wainwright Reiterates Buy on Halozyme (HALO), Maintains Price Target - MSN

May 31, 2025
pulisher
May 30, 2025

Halozyme to Participate at Upcoming Investor Conferences - Kilgore News Herald

May 30, 2025
pulisher
May 30, 2025

Halozyme Therapeutics (NASDAQ:HALO) Receives “Buy” Rating from HC Wainwright - Defense World

May 30, 2025
pulisher
May 29, 2025

Halozyme Therapeutics (HALO): HC Wainwright & Co. Reiterates Buy Rating | HALO Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications - Longview News-Journal

May 29, 2025
pulisher
May 29, 2025

Halozyme stock holds Buy rating, $72 target from H.C. Wainwright By Investing.com - Investing.com UK

May 29, 2025
pulisher
May 28, 2025

Halozyme to Participate at Upcoming Investor Conferences | HALO Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Halozyme CEO Sets Two Major Healthcare Conference Appearances: Goldman Sachs and Benchmark - Stock Titan

May 28, 2025
pulisher
May 28, 2025

3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO) - sharewise

May 28, 2025
pulisher
May 28, 2025

Bristol-Myers wins EU nod for Opdivo injectable developed with Halozyme - MSN

May 28, 2025
pulisher
May 28, 2025

Implied Volatility Surging for Halozyme Therapeutics Stock Options - The Globe and Mail

May 28, 2025
pulisher
May 28, 2025

Bristol Myers Squibb, Halozyme Get EC Approval for Subcutaneous Formulation of Opdivo - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Halozyme Says Bristol-Myers Squibb Gets EC Approval For Opdivo SC Developed With Halozyme's ENHANZE - Nasdaq

May 28, 2025
pulisher
May 28, 2025

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications | HALO Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

High Growth Tech Stocks To Watch In The US May 2025 - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

New Strong Buy Stocks for May 28th - The Globe and Mail

May 28, 2025
pulisher
May 18, 2025

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of “Hold” by Brokerages - Defense World

May 18, 2025
pulisher
May 16, 2025

J&J, Halozyme cut at Leerink on price control risk for combo products - MSN

May 16, 2025
pulisher
May 16, 2025

Halozyme Therapeutics (NASDAQ:HALO) Cut to “Strong Sell” at Leerink Partnrs - Defense World

May 16, 2025
pulisher
May 15, 2025

Halozyme downgraded at Morgan Stanley on price control risk - MSN

May 15, 2025
pulisher
May 15, 2025

Morgan Stanley Downgrades Halozyme Therapeutics (BIT:1HALO) - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Zacks.com featured highlights Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Morgan Stanley Downgrades Halozyme Therapeutics (LSE:0J2O) - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Leerink Partners Downgrades Halozyme Therapeutics (LSE:0J2O) - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Leerink Partners Downgrades Halozyme Therapeutics (NASDAQ:HALO) to Underperform - Defense World

May 15, 2025
pulisher
May 14, 2025

Halozyme (HALO) Downgraded by Morgan Stanley Amid Pricing Concer - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Leerink Partners Downgrades Halozyme Therapeutics (BMV:HALO) - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Halozyme Therapeutics (HALO) Downgraded by Morgan Stanley | HALO Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Halozyme, J&J slide as analyst cuts rating on CMS draft guidance - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Halozyme (HALO) Downgraded Amid Medicare Price Negotiation Conce - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Halozyme stock downgraded at Morgan Stanley (HALO:NASDAQ) - Seeking Alpha

May 14, 2025
pulisher
May 14, 2025

Halozyme Therapeutics downgraded by Morgan Stanley with a new price target - Quantisnow

May 14, 2025
pulisher
May 14, 2025

Why Halozyme Therapeutics, Inc. (HALO) Declined on Tuesday - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Halozyme stock holds $78 target despite Medicare concerns By Investing.com - Investing.com Canada

May 14, 2025
pulisher
May 14, 2025

Halozyme (HALO) Downgraded by Morgan Stanley Amid Pricing Concerns | HALO Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Halozyme stock holds $78 target despite Medicare concerns - Investing.com

May 14, 2025

Halozyme Therapeutics Inc (HALO) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$73.62
price up icon 1.21%
$22.20
price up icon 1.79%
$20.59
price up icon 4.36%
$33.78
price up icon 0.09%
$108.49
price down icon 1.51%
biotechnology ONC
$255.86
price down icon 0.44%
자본화:     |  볼륨(24시간):